Advertisement

Journal of Cancer Survivorship

, Volume 13, Issue 5, pp 653–662 | Cite as

Subjective cognitive functioning and associations with psychological distress in adult brain tumour survivors

  • Chelsea NicolEmail author
  • Tamara Ownsworth
  • Lee Cubis
  • William Nguyen
  • Matthew Foote
  • Mark B. Pinkham
Article

Abstract

Purpose

The impact of brain tumour on subjective cognitive function (SCF) has received little attention despite the implications of these perceptions for quality of life. SCF consists of two related yet distinct components, perceived cognitive impairment (PCI) and perceived cognitive abilities (PCA). This study compared the SCF of adult brain tumour survivors and healthy controls and examined demographic, illness-related, and psychological factors associated with SCF.

Method

Sixty-five adult survivors with primary brain tumour (age, 22–75 years), and 65 age- and sex-matched controls were recruited. Participants with brain tumour completed the Brief Test of Adult Cognition by Telephone, Functional Assessment of Cancer Therapy–Cognitive Function (FACT-Cog), ratings of physical symptoms, Depression Scale of the Depression Anxiety Stress Scales-21 (DASS-Depression), and Generalized Anxiety Disorder-7 (GAD-7) scale. Controls completed the FACT-Cog, DASS-Depression, and GAD-7.

Results

Adult brain tumour survivors reported significantly greater PCI and lower PCA than controls, after accounting for anxiety. Higher PCI was significantly related to fatigue, pain, treatment-related side-effects, anxiety, and depression. Lower PCA was significantly associated with fatigue, pain, poorer objective cognitive function, lower education, anxiety, and depression. Anxiety uniquely accounted for 9–14% of variance in SCF.

Conclusions

Adult brain tumour survivors were found to experience poorer SCF than healthy controls after accounting for anxiety. SCF was related to multiple factors after brain tumour; however, an independent association with anxiety was identified.

Implications for Cancer Survivors

These findings highlight the potential value of psychological interventions targeting anxiety and cognitive effects to improve quality of survivorship after brain tumour.

Keywords

Brain tumour survivors Patient-reported outcomes Perceived cognitive impairment Perceived cognitive abilities Psychological distress 

Notes

Acknowledgements

The authors would like to thank the Griffith University School of Applied Psychology for the publication scholarship, awarded to the first author. We would also like to thank all of the participants of the study.

Compliance with ethical standards

Ethical clearance was obtained through hospital and university ethics committees. Adult brain tumour survivors were approached by treating professionals who provided an overview of the study and obtained initial verbal consent for researchers to contact prospective participants. Informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Leece R, Xu J, Ostrom QT, Chen Y, Kruchko C, Barnholtz-Sloan JS. Global incidence of malignant brain and other central nervous system tumors by histology, 2003–2007. Neuro-Oncology. 2017;19(11):1553–64.  https://doi.org/10.1093/neuonc/nox091.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Ownsworth T, Hawkes AL, Chambers S, Walker DG, Shum D. Applying a biopsychosocial perspective to investigate factors related to emotional adjustment and quality of life for individuals with brain tumour. Brain Impairment. 2010;11(3):270–80.  https://doi.org/10.1375/brim.11.3.270.CrossRefGoogle Scholar
  3. 3.
    Ownsworth T, Henderson L, Chambers SK. Social support buffers the impact of functional impairments on caregiver psychological well-being in the context of brain tumor and other cancers. Psycho-Oncology. 2010;19(10):1116–22.  https://doi.org/10.1002/pon.1663.CrossRefPubMedGoogle Scholar
  4. 4.
    Gehrke AK, Baisley MC, Sonck AL, Wronski SL, Feuerstein M. Neurocognitive deficits following primary brain tumor treatment: systematic review of a decade of comparative studies. J Neuro-Oncol. 2013;115(2):135–42.  https://doi.org/10.1007/s11060-013-1215-2.CrossRefGoogle Scholar
  5. 5.
    Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev. 2012;38(7):926–34.  https://doi.org/10.1016/j.ctrv.2012.05.002.CrossRefPubMedGoogle Scholar
  6. 6.
    Ownsworth T. Coping with the unthinkable: psychosocial advances in the management of primary brain tumour. Brain Impairment. 2016;17(3):265–72.  https://doi.org/10.1017/BrImp.2016.19.CrossRefGoogle Scholar
  7. 7.
    Klein M, Taphoorn MJ, Heimans JJ, van der Ploeg HM, Vandertop WP, Smit EF, et al. Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. J Clin Oncol. 2001;19(20):4037–47.  https://doi.org/10.1200/jco.2001.19.20.4037.CrossRefPubMedGoogle Scholar
  8. 8.
    Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase iii trial. J Clin Oncol. 2004;22(1):157–65.  https://doi.org/10.1200/JCO.2004.05.128.CrossRefPubMedGoogle Scholar
  9. 9.
    Tucha O, Smely C, Preier M, Lange KW. Cognitive deficits before treatment among patients with brain tumors. Neurosurgery. 2000;47(2):324–33.  https://doi.org/10.1097/00006123-200008000-00011.CrossRefPubMedGoogle Scholar
  10. 10.
    Dwan TM, Ownsworth T, Chambers S, Walker DG, Shum DH. Neuropsychological assessment of individuals with brain tumor: comparison of approaches used in the classification of impairment. Front Oncol. 2015;5:56.  https://doi.org/10.3389/fonc.2015.00056.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Biglia N, Bounous V, Malabaila A, Palmisano D, Torta D, d'Alonzo M, et al. Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care. 2012;21(4):485–92.  https://doi.org/10.1111/j.1365-2354.2011.01320.x.CrossRefGoogle Scholar
  12. 12.
    Ganz PA, Petersen L, Castellon SA, Bower JE, Silverman DH, Cole SW, et al. Cognitive function after the initiation of adjuvant endocrine therapy in early-stage breast cancer: an observational cohort study. J Clin Oncol. 2014;32(31):3559–67.  https://doi.org/10.1200/JCO.2014.56.1662.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Janelsins MC, Kohli S, Mohile SG, Usuki K, Ahles TA, Morrow GR. An update on cancer-and chemotherapy-related cognitive dysfunction: current status. Semin Oncol. 2011;38(3):431–8.  https://doi.org/10.1053/j.seminoncol.2011.03.014.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Noggle CA, Dean RS. The neuropsychology of cancer and oncology. New York, NY: Springer Pub; 2013.Google Scholar
  15. 15.
    Gehring K, Taphoorn MJ, Sitskoorn MM, Aaronson NK. Predictors of subjective versus objective cognitive functioning in patients with stable grades II and III glioma. Neuro-Oncol Pract. 2015;2(1):20–31.  https://doi.org/10.1093/nop/npu035.CrossRefGoogle Scholar
  16. 16.
    Klein M, Heimans J, Aaronson N, Van der Ploeg H, Grit J, Muller M, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet. 2002;360(9343):1361–8.  https://doi.org/10.1016/s0140-6736(02)11398-5.CrossRefPubMedGoogle Scholar
  17. 17.
    Pranckeviciene A, Deltuva VP, Tamasauskas A, Bunevicius A. Association between psychological distress, subjective cognitive complaints and objective neuropsychological functioning in brain tumor patients. Clin Neurol Neurosurg. 2017;163:18–23.  https://doi.org/10.1016/j.clineuro.2017.10.007.CrossRefPubMedGoogle Scholar
  18. 18.
    Reid-Arndt SA, Hsieh C, Perry MC. Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer. Psycho-Oncology. 2010;19(5):535–44.  https://doi.org/10.1002/pon.1581.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs. 2006;11(1):6–15.  https://doi.org/10.1016/j.ejon.2006.02.005.CrossRefPubMedGoogle Scholar
  20. 20.
    Dhillon HM, Tannock IF, Pond GR, Renton C, Rourke SB, Vardy JL. Perceived cognitive impairment in people with colorectal cancer who do and do not receive chemotherapy. J Cancer Surviv. 2017;12:1–8.  https://doi.org/10.1007/s11764-017-0656-6.CrossRefGoogle Scholar
  21. 21.
    Janelsins MC, Heckler CE, Peppone LJ, Kamen C, Mustian KM, Mohile SG, et al. Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol. 2017;35(5):506–14.  https://doi.org/10.1200/JCO.2016.68.5826.CrossRefPubMedGoogle Scholar
  22. 22.
    Lange M, Heutte N, Morel N, Eustache F, Joly F, Giffard B. Cognitive complaints in cancer: the French version of the Functional Assessment of Cancer Therapy–Cognitive Function (FACT-Cog), normative data from a healthy population. Neuropsychol Rehabil. 2016;26(3):392–409.  https://doi.org/10.1080/09602011.2015.1036890.CrossRefPubMedGoogle Scholar
  23. 23.
    Mehnert A, Scherwath A, Schirmer L, Schleimer B, Petersen C, Schulz-Kindermann F, et al. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns. 2006;66(1):108–18.  https://doi.org/10.1016/j.pec.2006.11.005.CrossRefGoogle Scholar
  24. 24.
    Schagen SB, Boogerd W, Muller MJ, Ten Bokkel Huinink W, Moonen L, Meinhardt W, et al. Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol. 2008;47(1):63–70.  https://doi.org/10.1080/02841860701518058.CrossRefPubMedGoogle Scholar
  25. 25.
    Vardy JL, Stouten-Kemperman MM, Pond G, Booth CM, Rourke SB, Dhillon HM, et al. A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer. Brain Imaging Behav. 2017;13:1–12.  https://doi.org/10.1007/s11682-017-9728-5.CrossRefGoogle Scholar
  26. 26.
    Weis J, Poppelreuter M, Bartsch HH. Cognitive deficits as long-term side-effects of adjuvant therapy in breast cancer patients: ‘subjective’ complaints and ‘objective’ neuropsychological test results. Psycho-Oncology. 2009;18(7):775–82.  https://doi.org/10.1002/pon.1472.CrossRefPubMedGoogle Scholar
  27. 27.
    Green HJ, Pakenham KI, Gardiner RA. Cognitive deficits associated with cancer: a model of subjective and objective outcomes. Psychol Health Med. 2005;10(2):145–60.  https://doi.org/10.1080/13548500500093308.CrossRefGoogle Scholar
  28. 28.
    Jenkins V, Shilling V, Deutsch G, Bloomfield D, Morris R, Allan S, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006;94(6):828–34.  https://doi.org/10.1038/sj.bjc.6603029.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Cochereau J, Herbet G, Duffau H. Patients with incidental WHO grade II glioma frequently suffer from neuropsychological disturbances. Acta Neurochir. 2016;158(2):305–12.  https://doi.org/10.1007/s00701-015-2674-3.CrossRefPubMedGoogle Scholar
  30. 30.
    Wagner LI, Sweet J, Butt Z, Lai JS, Cella D. Measuring patient self-reported cognitive function: development of the functional assessment of cancer therapy-cognitive function instrument. J Support Oncol. 2009;7(6):W32–W9.Google Scholar
  31. 31.
    Lai J-S, Wagner LI, Jacobsen PB, Cella D. Self-reported cognitive concerns and abilities: two sides of one coin? Psycho-Oncology. 2014;23(10):1133–41.  https://doi.org/10.1002/pon.3522.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Joly F, Lange M, Rigal O, Correia H, Giffard B, Beaumont JL, et al. French version of the functional assessment of cancer therapy–cognitive function (FACT-Cog) version 3. Support Care Cancer. 2012;20(12):3297–305.CrossRefGoogle Scholar
  33. 33.
    Cheung YT, Lim SR, Shwe M, Tan YP, Chan A. Psychometric properties and measurement equivalence of the English and Chinese versions of the functional assessment of cancer therapy-cognitive in Asian patients with breast cancer. Value Health. 2013;16(6):1001–13.  https://doi.org/10.1016/j.jval.2013.06.017.CrossRefPubMedGoogle Scholar
  34. 34.
    Lovibond PF, Lovibond SH. Manual for the depression anxiety stress scales: Psychology Foundation of Australia; 1996.Google Scholar
  35. 35.
    Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.  https://doi.org/10.1001/archinte.166.10.1092.CrossRefPubMedGoogle Scholar
  36. 36.
    Ownsworth T, Little T, Turner B, Hawkes A, Shum D. Assessing emotional status following acquired brain injury: the clinical potential of the depression, anxiety and stress scales. Brain Inj. 2008;22(11):858–69.  https://doi.org/10.1080/02699050802446697.CrossRefPubMedGoogle Scholar
  37. 37.
    Arnold SD, Forman LM, Brigidi BD, Carter KE, Schweitzer HA, Quinn HE, et al. Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors. Neuro-Oncology. 2008;10(2):171–81.  https://doi.org/10.1215/15228517-2007-057.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.  https://doi.org/10.1200/jco.1993.11.3.570.CrossRefPubMedGoogle Scholar
  39. 39.
    Tun PA, Lachman ME. Telephone assessment of cognitive function in adulthood: The Brief Test of Adult Cognition by Telephone. Age Ageing. 2006;35(6):629–32.  https://doi.org/10.1093/ageing/afl095.CrossRefPubMedGoogle Scholar
  40. 40.
    Song M-K, Ward SE, Bair E, Weiner LJ, Bridgman JC, Hladik GA, et al. Patient-reported cognitive functioning and daily functioning in chronic dialysis patients: cognitive and daily functioning in dialysis patients. Hemodial Int. 2015;19(1):90–9.  https://doi.org/10.1111/hdi.12202.CrossRefPubMedGoogle Scholar
  41. 41.
    Jones S, Ownsworth T, Shum DH. Feasibility and utility of telephone-based psychological support for people with brain tumor: a single-case experimental study. Front Oncol. 2015;5:71.  https://doi.org/10.3389/fonc.2015.00071.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Hong WK, Bast RC, Hait WN, Kufe DW, Pollock RE, Weischselbaum RR, et al. Holland-Frei cancer medicine. 8th ed: PMPH-USA; 2010. p. 881.Google Scholar
  43. 43.
    Isaacs C, Rebbeck TR. Hereditary breast cancer. New York: Informa Healthcare; 2008. p. 99.Google Scholar
  44. 44.
    Eysenck MW, Calvo MG. Anxiety and performance: the processing efficiency theory. Cognit Emot. 1992;6(6):409–34.  https://doi.org/10.1080/02699939208409696.CrossRefGoogle Scholar
  45. 45.
    Robinson OJ, Vytal K, Cornwell BR, Grillon C. The impact of anxiety upon cognition: perspectives from human threat of shock studies. Front Hum Neurosci. 2013;7:203.  https://doi.org/10.3389/fnhum.2013.00203.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Vytal KE, Cornwell BR, Letkiewicz AM, Arkin NE, Grillon C. The complex interaction between anxiety and cognition: insight from spatial and verbal working memory. Front Hum Neurosci. 2013;7:93.  https://doi.org/10.3389/fnhum.2013.00093.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Wetherell JL, Wetherell JL, Reynolds CA, Reynolds CA, Gatz M, Gatz M, et al. Anxiety, cognitive performance, and cognitive decline in normal aging. J Gerontol - Series B Psychol Sci Soc Sci. 2002;57(3):P246–P55.  https://doi.org/10.1093/geronb/57.3.P246.CrossRefGoogle Scholar
  48. 48.
    Comijs H, Deeg D, Dik M, Twisk J, Jonker C. Memory complaints; the association with psycho-affective and health problems and the role of personality characteristics: a 6-year follow-up study. J Affect Disord. 2002;72(2):157–65.  https://doi.org/10.1016/S0165-0327(01)00453-0.CrossRefPubMedGoogle Scholar
  49. 49.
    McDougall GJ, Kang J. Memory self-efficacy and memory performance in older males. Int J Mens Health. 2003;2(2):131–47.  https://doi.org/10.3149/jmh.0202.131.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Malec JF, Brown AW, Moessner AM, Stump TE, Monahan P. A preliminary model for posttraumatic brain injury depression. Arch Phys Med Rehabil. 2010;91(7):1087–97.  https://doi.org/10.1016/j.apmr.2010.04.002.CrossRefPubMedGoogle Scholar
  51. 51.
    Armstrong TS. Symptoms experience: a concept analysis. Oncol Nurs Forum. 2003;30(4):601–6.  https://doi.org/10.1188/03.ONF.601-606.CrossRefPubMedGoogle Scholar
  52. 52.
    Piil K, Juhler M, Jacobsen J, Jarden M. Controlled rehabilitative and supportive care intervention trials in patients with high-grade gliomas and their caregivers: a systematic review. BMJ Support Palliat Care. 2016;6(1):27–34.  https://doi.org/10.1136/bmjspcare-2013-000593.CrossRefPubMedGoogle Scholar
  53. 53.
    Piet J, Würtzen H, Zachariae R. The effect of mindfulness-based therapy on symptoms of anxiety and depression in adult cancer patients and survivors: a systematic review and meta-analysis. J Consult Clin Psychol. 2012;80(6):1007–20.  https://doi.org/10.1037/a0028329.CrossRefPubMedGoogle Scholar
  54. 54.
    Pace A, Dirven L, Koekkoek JA, Golla H, Fleming J, Rudà R, et al. European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. Lancet Oncol. 2017;18(6):e330–e40.  https://doi.org/10.1016/S1470-2045(17)30345-5.CrossRefPubMedGoogle Scholar
  55. 55.
    Ownsworth T, Chambers S, Damborg E, Casey L, Walker DG, Shum DHK. Evaluation of the making sense of brain tumor program: a randomized controlled trial of a home-based psychosocial intervention. Psycho-Oncology. 2015;24(5):540–7.  https://doi.org/10.1002/pon.3687.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.School of Applied Psychology, Menzies Health Institute QueenslandGriffith UniversityMount GravattAustralia
  2. 2.School of MedicineUniversity of QueenslandSt LuciaAustralia
  3. 3.Department of Radiation OncologyPrincess Alexandra HospitalWoolloongabbaAustralia

Personalised recommendations